Peter A. Meredith

Peter A. Meredith's AcademicInfluence.com Rankings

Peter A. Meredith

Philosophy

#9876

World Rank

#13497

Historical Rank

Logic

#6829

World Rank

#8380

Historical Rank

philosophy Degrees

Peter A. Meredith

Biology

#13573

World Rank

#17125

Historical Rank

Biochemistry

#2385

World Rank

#2535

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Peter A. Meredith's Degrees

Doctorate Medicine Stanford University

Why Is Peter A. Meredith Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter A. Meredith's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? (1998) (542)
Clinical Pharmacokinetics of Amlodipine (1992) (220)
Bioequivalence and other unresolved issues in generic drug substitution. (2003) (205)
Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. (1999) (120)
ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. (1998) (110)
Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. (1983) (87)
Long-Term and Ultra Long–Term Blood Pressure Variability During Follow-Up and Mortality in 14 522 Patients With Hypertension (2013) (85)
A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. (1982) (82)
A RETROSPECTIVE ANALYSIS OF BLOOD-LEAD IN MENTALLY RETARDED CHILDREN (1977) (81)
Pharmacokinetics of calcium antagonists. (1988) (78)
Enalapril Clinical Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships (1993) (72)
The effect of calcium on lead absorption in rats. (1977) (65)
CONTRIBUTION OF LEAD IN DRINKING WATER TO BLOOD-LEAD (1977) (65)
The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. (1988) (64)
Effects of aluminium, lead and zinc on delta-aminolaevulinic acid dehydratase. (1977) (64)
Cancer risk of hypertensive patients taking calcium antagonists (1998) (64)
The effect of captopril on the reflex control heart rate: possible mechanisms. (1985) (62)
Theophylline-salbutamol interaction: bronchodilator response to salbutamol at maximally effective plasma theophylline concentrations. (1981) (61)
The percutaneous absorption of lead-203 in humans from cosmetic preparations containing lead acetate, as assessed by whole-body counting and other techniques. (1980) (60)
Kinetic-dynamic relations and individual responses to enalapril. (1990) (59)
Delta-aminolaevulinic acid metabolism in normal and lead-exposed humans. (1978) (59)
Pharmacokinetic overview of doxazosin. (1987) (58)
Blood pressure variability and its implications for antihypertensive therapy. (1995) (58)
Immediate cardiovascular responses to oral prazosin—Effects of concurrent β‐blockers (1981) (57)
Nifedipine: Individual Responses and Concentration‐Effect Relationships (1988) (54)
Verapamil pharmacokinetics and apparent hepatic and renal blood flow. (1985) (52)
Phase I and pharmacokinetic study of D-verapamil and doxorubicin. (1991) (52)
Clinical pharmacological aspects of calcium antagonists and their therapeutic role in hypertension. (1985) (51)
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. (2008) (50)
The Relationships Between Dose and Antihypertensive Effect of Four AT 1 -receptor Blockers. Differences in Potency and Efficacy (2002) (46)
Clinical pharmacological studies with doxazosin. (1986) (46)
Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. (1999) (45)
Pharmacodynamic modeling of the antihypertensive response to amlodipine (1993) (45)
Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS (2012) (45)
Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms (2009) (44)
Combination of Nifedipine and Doxazosin in Essential Hypertension (1992) (44)
HEPATIC DRUG METABOLISM AND HAEM BIOSYNTHESIS IN LEAD‐POISONED RATS (1978) (43)
Methodological considerations in calculation of the trough: peak ratio (1994) (43)
Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. (2004) (42)
Clinical Pharmacokinetics of Prazosin — 1985 (1985) (42)
FDA Guidelines on Trough: Peak Ratios in the Evaluation of Antihypertensive Agents (1994) (41)
Concentration-effect relationships and individual responses to doxazosin in essential hypertension. (1989) (40)
Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects (1984) (40)
Prediction of the antihypertensive response to enalapril. (1989) (39)
Initial blood pressure as a predictor of the response to antihypertensive therapy. (1988) (38)
Differential Effects of a Missed Dose of Trandolapril and Enalapril on Blood Pressure Control in Hypertensive Patients (1995) (37)
Review: From Hypertension to Heart Failure — Are There Better Primary Prevention Strategies? (2006) (37)
Therapeutic implications of drug "holidays'. (1996) (36)
Erythrocyte delta-aminolaevulinic acid dehydratase activity and blood protoporphyrin concentrations as indices of lead exposure and altered haem biosynthesis. (1979) (35)
Hematocrit Predicts Long-Term Mortality in a Nonlinear and Sex-Specific Manner in Hypertensive Adults (2012) (34)
The Effects of Aluminium, Lead and Zinc on δ-Aminolaevulinic Acid Dehydratase (1974) (34)
Acetaminophen Use and Risk of Myocardial Infarction and Stroke in a Hypertensive Cohort (2015) (34)
Oral pharmacokinetics of omeprazole (2004) (33)
Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. (1977) (32)
Generic Drugs (1996) (32)
A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. (1988) (32)
Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide (2005) (31)
Concentration-effect analysis of antihypertensive drug responses. (1990) (29)
The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. (1985) (29)
The pharmacokinetics of doxazosin in elderly normotensives. (1986) (28)
Differences between calcium antagonists: duration of action and trough to peak ratio (1993) (28)
The contribution of drinking water lead to maternal blood lead concentrations. (1979) (28)
Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. (1996) (28)
Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 3: Safety, efficacy, tolerability and duration of action (1993) (28)
Cardiac effects of lead in drinking water of rats. (1975) (26)
Lead exposure and renal failure: does renal insufficiency influence lead kinetics? (1981) (26)
British Journal of Clinical Pharmacology (2013) (26)
A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. (1991) (25)
A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects. (1993) (25)
The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection. (1981) (25)
Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. (1985) (24)
Are fixed-dose combination antihypertensives suitable as first-line therapy? (2012) (24)
Is Postural Hypotension a Real Problem with Antihypertensive Medication? (2001) (24)
Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man. (1985) (23)
Clinical Comparative Trials of Angiotensin II Type 1 (AT 1 )-Receptor Blockers (2001) (23)
Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. (1984) (23)
The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects (1987) (23)
Application of Pharmacokinetic-Pharmacodynamic Modelling for the Comparison of Quinazoline α-Adrenoceptor Agonists in Normotensive Volunteers (1985) (23)
Kinetics of lead following intravenous administration in man. (1984) (22)
The combination of prazosin and verapamil in the treatment of essential hypertension (1988) (21)
Changes in serum aluminium, blood zinc, blood lead and erythrocyte δ-aminolaevulinic acid dehydratase activity during haemodialysis (1979) (21)
Acetaminophen use and change in blood pressure in a hypertensive population (2013) (21)
The association between lead concentrations in teeth and domestic water lead concentrations. (1978) (21)
Clinical Studies with the Potassium Channel Activator Cromakalim in Normotensive and Hypertensive Subjects (1990) (21)
Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure (2007) (20)
The effects of industrial lead poisoning on cytochrome P450 mediated phenazone (antipyrine) hydroxylation (1977) (19)
Trough: peak ratio and smoothness index for antihypertensive agents. (1999) (19)
Effect of Calcium Channel Blockers on Adrenergic and Nonadrenergic Vascular Responses in Man (1985) (19)
The storage of samples for blood and water lead analysis. (1977) (19)
The in vivo effects of zinc on erythrocyte delta-aminolaevulinic acid dehydratase in man (1980) (18)
Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man. (1993) (18)
Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. (1987) (17)
Lead exposure and changes in the renin-angiotensin-aldosterone system in man. (1985) (17)
Importance of sustained and “tight” blood pressure control in patients with high cardiovascular risk (2016) (17)
Pharmacokinetic-Pharmacodynamic Relationships of α-Adrenoceptor Antagonists (1989) (17)
An Evaluation of the Pharmacodynamics and Pharmacokinetics of Nicardipine Combined with Enalapril in Essential Hypertension (1987) (17)
Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension (2010) (17)
Action of lead on neurotransmission in rats. (1989) (17)
Relationship between plasma prazosin concentrations and α‐antagonism in humans: Comparison of conventional and rate‐controlled (Oros) formulations (1988) (16)
The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. (1991) (16)
Effects of lead exposure on rat brain catecholaminergic neurochemistry. (1988) (16)
Amlodipine; clinical relevance of a unique pharmacokinetic profile. (1993) (16)
Clinical Pharmacological Studies on the Interaction Between α‐Adrenoceptors and Calcium Antagonists (1985) (16)
Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. (1999) (16)
An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. (1992) (16)
Is cancer related to hypertension or to its treatment? (1999) (15)
Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril (1992) (15)
Predictability of antihypertensive responsiveness and α‐adrenoceptor antagonism during prazosin treatment (1989) (15)
Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why? (1999) (15)
A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices (2004) (15)
Clinical relevance of optimal pharmacokinetics in the treatment of hypertension (1997) (15)
The influence of age on the pharmacokinetics of verapamil. (1991) (14)
Antihypertensive treatment and trough: peak ratio general considerations (1994) (14)
Comparison of the Oral Angiotensin II Receptor Antagonist UP 269–6 or Enalapril 20 mg on Blood Pressure and Neurohormonal Effects in Salt‐Deplete Man (1995) (14)
Controlled‐Release Doxazosin as Combination Therapy in Hypertension: The GATES Study (2006) (14)
The description and prediction of antihypertensive drug response: an individualised approach. (1991) (13)
Pharmacokinetics and pharmacodynamics of trimazosin in man. (1983) (13)
Clinical pharmacology of selective alpha blockers. Hemodynamics and effects on lipid levels. (1987) (13)
Antihypertensive drugs: individualized analysis and clinical relevance of kinetic-dynamic relationships. (1992) (13)
Concentration-Effect Analysis of Antihypertensive Drug Response (1994) (13)
The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension. (1989) (13)
The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. (1983) (12)
Erythrocyte Delta‐aminolaevulinic Acid Dehydratase Activity and changes in Delta‐aminolaevulinic Acid Concentration in Various Forms of Anaemia (1978) (12)
Influence of lead exposure on catecholamine metabolism in discrete rat brain nuclei. (1988) (12)
The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects (2004) (12)
A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS) (2013) (12)
Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the ‘ACTION' database in patients with angina (2010) (12)
EDITORIAL: Trough peak ratio clinically useful or practically irrelevant? (1995) (11)
Trough/peak ratios for antihypertensive agents. The issues in perspective. (1994) (11)
The carcinogenicity of lead (1978) (11)
Differential effects of ACE inhibiting drugs: Evidence for concentration‐, dose‐, and agent‐dependent responses (1993) (11)
THE EFFECT OF INDUSTRIAL LEAD POISONING ON CYTOCHROME P-450 MEDIATED PHENAZONE HYDROXYLATION (1977) (10)
The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. (1991) (10)
Concentration-effect relationships and implications for trough-to-peak ratio. (1996) (10)
The determination of trimazosin and its metabolite CP23445 in whole blood by high performance liquid chromatography using fluorescence detection. (1984) (10)
Zinc, copper and δ-aminolaevulinic acid dehydratase in vitro and in vivo (1981) (10)
Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. (1996) (10)
Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans. (1986) (10)
The Effects of Zinc and Lead on δ-Aminolaevulinate Dehydratase (1978) (10)
Achieving Quality 24-h Blood Pressure Control with Candesartan Cilexetil (2000) (10)
Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure (2004) (9)
DOXAZOSIN,AN a-ADRENOCEPTORANTAGONIST: PHARMACOKINETICSAND CONCENTRATION- EFFECTRELATIONSHIPSINMAN (1983) (9)
Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. (1994) (9)
Dose-response clarification in early drug development. (1991) (9)
Therapeutic coverage: reducing the risks of partial compliance. (1994) (9)
Pharmacokinetics of nifedipine. (1985) (9)
Achieving and Assessing Therapeutic Coverage (2002) (9)
R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate. (1993) (9)
Acute hypotensive response to nifedipine added to prazosin (1984) (9)
The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine. (1991) (9)
Ketanserin concentration-effect relationships in individual hypertensive patients. (1988) (9)
Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite (1983) (8)
Role of trough to peak efficacy in the evaluation of antihypertensive therapy. (1998) (8)
Efficacy and Tolerability of Long-Term Rilmenidine Treatment in Hypertensive Diabetic Patients (2004) (8)
Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man (2005) (8)
The influence of lead on haem biosynthesis and biodegradation in the rat [proceedings]. (1979) (8)
Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk (2011) (8)
A clinical pharmacological assessment of doxazosin and enalapril in combination. (1993) (8)
Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers. (1985) (8)
Long‐acting calcium antagonists: amlodipine versus nifedipine gastrointestinal therapeutic system (GITS) (1993) (7)
Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists. (1989) (7)
A putative placebo comparison of the SCOPE and LIFE trials (2004) (7)
ACE inhibition and AT1 receptor blockers: efficacy and duration in hypertension (2000) (7)
Organ protection and optimal blood pressure control. (1995) (7)
Penetration of enoxacin into lung tissue. (1989) (7)
Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses. (2012) (7)
Antihypertensive treatment and trough: peak ratio (1994) (7)
New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responses. (1994) (7)
How to evaluate the duration of blood pressure control: the trough:peak ratio and 24-hour monitoring. (1998) (7)
Trimazosin: Relationships Between Hypotensive Effect, Vascular Responsiveness, and Drug and Metabolite Concentrations (1985) (7)
Trimazosin in normotensive subjects (1984) (7)
The Pharmacokinetics of Ramipril in a Group of Ten Elderly Patients with Essential Hypertension (1991) (7)
Enhancing patients' compliance (1998) (7)
Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study. (2004) (7)
The Unique Adalat Story – Nifedipine Gastrointestinal Therapeutic System (2007) (7)
Labetalol and the Management of Hypertension (1981) (6)
Analysis of trough:peak ratio and the assessment of anti-hypertensive drug action. (1995) (6)
Pharmacokinetics of spirapril in renal impairment. (1994) (6)
An additive or synergistic drug interaction: Application of concentration‐effect modeling (1992) (6)
Neurohormonal and Blood Pressure Responses to Low-Dose Infusion of an Orally Active Renin Inhibitor, Ro 42-5892, in Salt-Replete Men (1992) (6)
Efficacy of low-density-lipoprotein lowering with statins (1994) (6)
EFFECTS OF AGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CARDIOVASCULAR DRUGS: APPLICATION OF CONCENTRATION‐EFFECT MODELING. 3. TRIMAZOSIN (1995) (6)
Prediction and optimisation of the antihypertensive response to nifedipine. (1994) (6)
Intrinsically long-acting agents compared with long-acting chronoformulations. (2000) (6)
A Chronotherapeutic Approach to Effective Blood Pressure Management (2000) (6)
The pharmacokinetics of bucindolol and its major metabolite in essential hypertension. (1985) (5)
The Effects of Age on the Pharmacodynamics and Pharmacokinetics of Two Formulations of Verapamil (1989) (5)
Low-dose verapamil in middle-aged and elderly patients with angina pectoris: No evidence of increased susceptibility to the cardiac effects (1992) (5)
Calculation of trough-to-peak ratio in the research unit setting. Advantages and disadvantages. (1996) (5)
Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties. (1984) (5)
Prediction of response to antihypertensive therapy with enalapril and nifedipine. (1989) (5)
Pressor responsiveness in essential hypertension and the effects of treatment with an alpha blocker, calcium antagonist or ACE inhibitor. (1989) (5)
A novel statistical approach for the comparison of analytical methods to measure angiotensin converting enzyme activity, enalaprilat, and benazeprilat. (1993) (5)
Factors determining the response to calcium antagonists in hypertension. (1988) (5)
Verapamil and prazosin in essential hypertension: evidence of a synergistic combination? (1987) (5)
The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin (2004) (4)
Verapamil pharmacokinetics [letter] (1986) (4)
V-011 ONCE DAILY NIFEDIPINE: THE FORMULATION DICTATES THE PHARMACO KINETIC CHARACTERISTICS AND THE THERAPEUTIC RESPONSES (2011) (4)
The Effect of Carbon Monoxide upon Erythrocyte δ-Aminolevulinicacid . Dehydratase Activity (1979) (4)
Modern strategies in hypertension management (2004) (4)
The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol. (1991) (4)
24 Vascular pressor responses in treated and untreated essential hypertension (1988) (4)
A clinical pharmacological study of nifedipine and lisinopril alone and in combination. (1987) (4)
Modelling the pharmacokinetics and pharmacodynamics of trimazosin. (1986) (4)
THE EFFECTS OF AGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CARDIOVASCULAR DRUGS: APPLICATION OF CONCENTRATION–EFFECT MODELING. 2. ACEBUTOLOL (1995) (3)
13 Antihypertensive Response and Individual Concentration-Effect Relationships (1987) (3)
The effects of lead on the renin-angiotensin system. (1985) (3)
Angiotensin-receptor blockade, cancer, and concerns. (2010) (3)
A032: Outcome differences between ACE inhibitor and calcium channel blocker treated hypertensives (2000) (3)
Assessment of the PKU card as a retrospective index of neonatal blood lead status. (1979) (3)
Angiotensin II antagonists for hypertension: there are differences in efficacy. (2001) (3)
Do ace inhibitors reduce mortality in hypertensive patients (1998) (3)
Verapamil pharmacokinetics. (1986) (3)
The effect of salbutamol on airways following maximal response to theophylline [proceedings]. (1980) (3)
Haem biosynthesis and hydroxylation of phenazone during lead intoxication. (1976) (3)
An evaluation of the use of haem-biosynthetic parameters in the detection of industrial and environmental lead exposure: delta-aminolaevulinic acid and coproporphyrin [proceedings]. (1979) (3)
The effects of lead on catecholamine metabolism in rat brain regions (1981) (3)
Is end stage renal disease a common outcome among patients attending a hypertension clinic (2008) (3)
The importance of sustained blood pressure control. (2000) (3)
Neurotoxic action of lead: effect on tetrahydrobiopterin metabolism in the rat. (1985) (2)
Enalapril in essential hypertension: the comparative effects of additional placebo, nicardipine and chlorthalidone. (1987) (2)
CALCIUM-CHANNEL BLOCKERS AND CANCER. AUTHORS' REPLIES (1996) (2)
Acute and Chronic Nifedipine in Essential Hypertension: Concentration-Effect Relationships (1987) (2)
Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects. (1991) (2)
THE EFFECTS OF AGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CARDIOVASCULAR DRUGS: APPLICATION OF CONCENTRATION–EFFECT MODELING. 1. TOLMESOXIDE (1995) (2)
Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives. (1984) (2)
Amlodipine--does the effect-time profile directly reflect the concentration-time profile throughout a 24-hour period? (1994) (2)
The influence of age on the pharmacokinetics and antihypertensive responses to dilevalol. (1990) (2)
Comments on systematic review of clinical‐ and cost‐effectiveness of candesartan and losartan in hypertension and heart failure (2011) (2)
OUTCOME DIFFERENCES BETWEEN ACE INHIBITOR AND CALCIUM CHANNEL BLOCKER TREATED HYPERTENSIVE PATIENTS: P3.25 (2000) (2)
Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. (1988) (2)
antihistamine andconcentration-ef fect relationship ofebastine inhealthy subjects (1988) (2)
An Evaluation of the Use of Haem-Biosynthetic Parameters in the Detection of Industrial and Environmental Lead Exposure: Erythrocyte δ-Aminolaevulinate Dehydratase and Blood Protoporphyrin Concentrations (1979) (2)
Zinc, copper and delta-aminolaevulinic acid dehydratase in vitro and in vivo. (1981) (1)
The student clinicopathologic conference, a device for the teaching of advanced pathology. (1950) (1)
Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system (2016) (1)
Clinical pharmacological evaluation of calcium antagonists and other drugs modifying myogenic tone in essential hypertension. (1989) (1)
DO ace inhibitors protect against cancer (1998) (1)
Hypertension & related disorders (2003) (1)
Counter-regulatory effects of combined ACE inhibition and calcium antagonism. (1988) (1)
Comparison of medroxalol and labetalol, drugs with combined a- and ,8-adrenoceptor antagonist properties (2006) (1)
Efficacy of low-density-lipoprotein lowering with statins. (1994) (1)
Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine. (1984) (1)
Thrapeutic equivalence in the treatment of hypertension: Can lercanidipine and nifedipine GITS be considered to be interchangeable? (2014) (1)
Trough/Peak Ratios for Antihypertensive Agents (1994) (1)
Evaluation of an antihypertensive therapy utilising meta-analysis of a clinical trial database. (2000) (1)
Factors determining the response to angiotensin-converting enzyme inhibitors in hypertension. (1990) (1)
Drug safety (2007) (1)
An evaluation of the use of haem-biosynthetic parameters in the detection of industrial and environmental lead exposure: erythrocyte delta-aminolaevulinate dehydratase and blood protoporphyrin concentrations. [proceedings]. (1979) (1)
The effects of zinc and lead on delta-aminolaevulinate dehydratase [proceedings]. (1978) (1)
Do pharmacologic differences among antihypertensive agents point to clinical benefits? (1999) (1)
Clinical Pharmacokinetics of Nifedipine (1997) (1)
Acuteandchronic ketanserin inessential hypertension: antihypertensive mechanisms andpharmacokinetics (1987) (1)
Calculation of Trough-to-Peak Ratio (1996) (1)
The relationships between initial blood pressure and the response to different antihypertensive agents. (2007) (1)
The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. (1992) (1)
An efficacy and safety study of doxazosin gastrointestinal therapeutic system as combination therapy in hypertensive patients (2004) (1)
Effect of lead on tetrahydrobiopterin levels in rat brain (1985) (1)
9C.08: HEART RATE AS A PREDICTOR OF CARDIOVASCULAR OUTCOMES NEW EVIDENCE FROM THE ACTION TRIAL DATABASE (2015) (0)
A comparative assessment oftheduration ofaction of amlodipine andnifedipine GITSinnormotensive subjects (1993) (0)
Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the “ACTION” database (2009) (0)
Cardiovascular outcomes after first-ever treatment of hypertension with angiotensin converting enzyme inhibitors or calcium channel-blockers in primary care (2003) (0)
Exclusion of non-responses (1996) (0)
Concentration-effect relationships and antihypertensive mechanisms: ketanserin in the treatment of essential hypertension. (1990) (0)
Therapy in the elderly hypertensive (2002) (0)
Bioavailability study of a concentrated suspension of phenytoin in healthy volunteers (1992) (0)
Introduction (2001) (0)
Alterations of dihydropteridine reductase activity by lead (1985) (0)
Introduction (2001) (0)
Review article Are fixed-dose combination antihypertensives suitable as first-line therapy? (2012) (0)
Cancer risk in hypertensive patients treated with calcium channel blockers (1998) (0)
Comparison oftheclinical pharmacokinetics andconcentration- effect relationships formedroxalol andlabetalol (1984) (0)
Antihypertensive treatment: full 24 hour control and trough to peak ratio. (1999) (0)
Measurement of Trough Blood Pressure (1996) (0)
A062: Steady state PK of doxazosin GITS versus doxazosin standard and the potential benefits of GITS in the treatment of hypertensive patients (2000) (0)
Thepharmacokinetics ofdoxazosin inelderly normotensives (1986) (0)
C-001 EFFECTS OF LONG ACTING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS ON SYMPATHETIC ACTIVITY IN HYPERTENSION: A COMPARISON OF AMLODIPINE AND NIFEDIPINE GITS (2011) (0)
Reports of Societies (1982) (0)
Concentration-effect relationships for antihypertensive drugs (1998) (0)
More drugs and better blood pressure control lead to improved cardiovascular outcomes: evidence from the ACTION database (2013) (0)
P-485: High pulse pressure does not predict cardiovascular mortality in a general population of hypertensives (2003) (0)
Wednesday May 28, Ballroom C, 12:00 pm Achieving Comprehensive Hypertension Management: Trough peak ratios: Are there differences between antihypertensive drugs? (1997) (0)
Adimolol, a long acting beta-adrenoceptor blocker in man. (1987) (0)
Adimolol, a long acting 3-adrenoceptor blocker in man prolonged 13-adrenoceptor antagonism (2006) (0)
P-172: A placebo-controlled comparison of the effects of doxazosin GITS 4mg and doxazosin standard 1mg on blood pressure and heart rate (2005) (0)
Evaluation of endpoints in hypertension: blood pressure. (1997) (0)
A COMPARATIVE ANALYSIS OF LERCANIDIPINE AND AMLODIPINE IN THE MANAGEMENT OF HYPERTENSION: PP.15.409 (2011) (0)
Kinetic‐dynamic relationships and antihypertensive mechanisms of ketanserin in essential hypertension (1988) (0)
Acute Versus Chronic Dosing Studies (1996) (0)
The effect of carbon monoxide upon erythrocyte delta-aminolevulinicacid dehydratase activity. (1979) (0)
A PHARMACODYNAMIC AND PHARMACOKINETIC ASSESS- MENT OFA NEW a-ADRENOCEPTORANTAGONIST,DOXAZOSIN (UK33274) INNORMOTENSIVE SUBJECTS (1982) (0)
Responsiveness to Calcium Antagonists in Essential Hypertension: Pharmacokinetic and Neurohumoral Aspects (1989) (0)
DOXAZOSIN GASTROINTESTINAL THERAPEUTIC SYSTEM AS COMBINATION THERAPY IN HYPERTENSIVE PATIENTS: AN EFFICACY AND SAFETY STUDY (GATES) (2004) (0)
Pharmacology of non-compliance (1997) (0)
Drug safety (1993) (0)
3.6 Cancer risk and use of calcium antagonists for hypertension (1997) (0)
Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment (2004) (0)
A PUTATIVE PLACEBO COMPARISON OF THE SCOPE AND LIFE TRIALS: OP 083 (2004) (0)
The physiologically realistic characterisation of benazeprilat pharmacokinetics in young and elderly volunteers (1990) (0)
BLOOD PRESSURE CONTROL & CARDIOVASCULAR OUTCOME IN CORONARY ARTERY DISEASE: EVIDENCE FROM THE ACTION TRIAL: 6C.06 (2011) (0)
A dose-ranging study ofUK-68,798, anovel class III anti-arrhythmic agent, innormal volunteers (1991) (0)
G-006 CARDIOVASCULAR OUTCOMES IN HYPERTENSIVES TREATED EXCLUSIVELY WITH NIFEDIPINE GITS OR CO-AMILOZIDE: EVIDENCE FROM THE “INSIGHT” DATABASE (2011) (0)
PROGNOSTIC VALUE OF BLOOD PRESSURE IN PATIENTS WITH CORONARY ARTERY DISEASE: EVIDENCE FROM THE ACTION TRIAL DATABASE: 9A.05 (2010) (0)
Serum uric acid and stroke in hypertension: Influence of gender (2007) (0)
The Pharmacokinetics and Pharmacodynamics of Verapamil in Elderly Hypertensives (1988) (0)
Therapy in the elderly hypertensive (2002) (0)
PHARMACOKINETICS OF DOXAZOSIN GASTROINTESTINAL THERAPEUTIC SYSTEM (DOX GITS) VERSUS DOXAZOSIN STANDARD: POTENTIAL BENEFITS OF DOX GITS IN THE TREATMENT OF PATIENTS WITH HYPERTENSION (2000) (0)
Cross-over versus sequential study design (1996) (0)
ACE INHIBITORS AND OUTCOME IN TREATED HYPERTENSIVE PATIENTS: P3.229 (2000) (0)
Efficacy and safety of long-acting nifedipine (GITS) in patients with diabetes and symptomatic stable angina pectoris: insights from the ACTION trial (2009) (0)
Is it time to review the treatment strategies in hypertension guidelines (2009) (0)
The effect of cimetidine on the pharmacokinetics, pharmacodynamics and alpha1-adrenoceptor responsiveness of trimazosin in man (2004) (0)
Concentration Effect Analysis of the Prazosin Derivatives, Trimazosin and Doxazosin (1982) (0)
G-015 PROGNOSTIC VALUE OF BLOOD PRESSURE AND “EARLY” BLOOD PRESSURE CONTROL IN PATIENTS WITH CORONARY ARTERY DISEASE: EVIDENCE FROM THE “ACTION” DATABASE (2011) (0)
Paroxysmal tachycardia, low nodal in origin, benefited by cardiac sympathectomy. (1948) (0)
Insights in the Management of Hypertension: Focus on Amlodipine (2001) (0)
Patient compliance. (1992) (0)
The effect of food on the pharmacokinetics and pharmacodynamics of tolmesoxide in essential hypertensives (2004) (0)
A PHARMACODYNAMIC AND PHARMACOKINETIC ASSESS- MENT OFANEWa-ADRENOCEPTOR ANTAGONIST, DOXAZOSIN (UK33274) IN NORMOTENSIVE SUBJECTS (2006) (0)
Letter: Antipyrine half life and clearance in clinical practice. (1976) (0)
Evolving strategies in cardiovascular care: The renin-angiotensin system and the future - Discussion (2000) (0)
Achieving quality 24-h blood pressure control with candesartan cilexetil. (2000) (0)
Angiotensin II receptor antagonists: new paradigms in the treatment of hypertension. Introduction. (2001) (0)
Pharmacokinetics of endralazine (2004) (0)
PHARMACOLOGY OF A CALCIUM T-CHANNEL SELECTIVE BLOCKER (1997) (0)
A031: ACE inhibitors and outcome in treated hypertensive patients (2000) (0)
Abstract W P165: Acetaminophen Use and Risk of Stroke and Myocardial Infarction in a Hypertensive Population (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter A. Meredith?

Peter A. Meredith is affiliated with the following schools:

Peter A. Meredith's Academic­Influence.com Rankings

Peter A. Meredith's Degrees

Why Is Peter A. Meredith Influential?

Peter A. Meredith's Published Works

Published Works

What Schools Are Affiliated With Peter A. Meredith?

Peter A. Meredith's AcademicInfluence.com Rankings